MedTrace Logo

A PK Study of IkT-148009 in Older and Elderly Healthy Subjects

NCT06644326 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-10-16

No results posted yet for this study

Summary

This is a two-part study. Part A consists of two different IkT-148009-201 solid dosage formulations that are being evaluated to determine their steady-state pharmacokinetic profile.

Part B is a drug-drug interaction (DDI) study focused on evaluating the impact of a strong CYP3A inhibitor on the preferred dosage determined in part A.

Conditions

  • Healthy

Interventions

DRUG

100mg IkT-148009 Wet

100mg wet tablet formulation

DRUG

200 mg Itraconazole

2 100mg capsules

DRUG

100mg IkT-148009 Dry

100mg dry tablet formulation

DRUG

50mg IkT-148009 Wet

50mg wet tablet formulation

Sponsors & Collaborators

  • ABLi Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-08-17
Completion
2024-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644326 on ClinicalTrials.gov